ON/OFF Stimulation and Impulsivity in Patients With Deep Brain Stimulators
NCT ID: NCT01506206
Last Updated: 2024-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2012-02-29
2024-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Magnetic Stimulation
NCT02704117
Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers
NCT02355002
Efficacy and Influencing Factors of Deep Transcranial Magnetic Stimulation in the Treatment of OCD
NCT06692114
Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?
NCT02029963
Deep Brain Stimulation and Obsessive-compulsive Disorder
NCT01329133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stop-Signal Task To measure "impulsive action," the investigators will use the stop-signal task (SST), a well-validated measure of response inhibition known to be impaired in substance abusers. In each of the 192 trials (3 blocks of 64; 10s interval between blocks, 2s ISI), subjects see a fixation cue (250ms) that is replaced by a shape (square or circle). Participants are told to make a shape judgment by pressing the appropriate computer key. On no-signal trials (75%), subjects are instructed to respond to the stimulus as fast and accurately as possible. On stop-signal trials (25%), the stimulus is followed by an auditory stop signal, and subjects are instructed to withhold responding. On stop-signal trials, a stop signal is presented after a variable delay (SSD), initially set at 250 msec and adjusted continuously with a staircase procedure by 50ms depending on whether inhibition is successful (increases) or unsuccessful (decreases). The paradigm will be administered using precompiled software provided by Gordon Logan, which automatically analyzes all relevant dependent variables (e.g stop-signal reaction time \[SSRT\] and GoRT). This task takes approximately 20 minutes.
Rewarded Variant This task is a variant of the above, with an inclusion of a "points possible cue" (2 or 50 points) for 500 ms, and followed by a brief delay (500-1500 ms) prior to the target. The task will be presented in 13 blocks. The first contains only go trials, from which the initial SSD will be calculated. The 12 subsequent blocks each consist of 40 trials; 18 standard go trials, 12 high reward (HR) go trials, 6 standard stop trials, and 4 HR stop trials, presented in random order. The SSD will be determined by a simple staircase-tracking algorithm as described by Logan, in which the SSD is adjusted up or down by 25 ms in order to establish an SSD that produces 50% accuracy of successful performance, with separate staircases calculated for the HR and standard trials. Outcome measures are the standard and high reward GoRTs, the standard and HR SSRTs, and the proportion of responses that would have been unsuccessfully stopped on HR trials if the standard SSD were utilized instead of the HR SSD.
Rewarded Go/NoGo Task In this task, participants are asked to make, or withhold, a button press to one of six stimuli (shapes), that correspond to six trial types: Go (no reward), Go (low reward), Go (high reward), NoGo (no reward), NoGo (low reward), NoGo (high reward). Participants are asked to press a button for Go stimuli and withhold a button press for NoGo stimuli. The ratio of Go stimuli to NoGo stimuli is approximately 15:1. Participants win money for correctly pressing a button for Go stimuli and for withholding a response for NoGo stimuli; conversely, they lose money for failing to respond to a Go stimuli or for failing to withhold a response to NoGo stimuli. There are 1260 trials, and each lasts 1 second. The task takes about 20 minutes to complete. Task may be administered without reward contingencies. In this case, there will only be two trial types: Go and NoGo.
Delay Discounting Task To measure "impulsive choice" the investigators will use a delay-discounting (DD) paradigm101. On each trial, participants make a binary choice between a smaller/sooner and a larger/later reward. The delay of the sooner reward is set as today, 2 weeks, \& 1 month; the delay of the later reward ranges from 2 to 6 weeks after the early reward. The sooner reward is from 1% to 50% less than the late reward (max = $40). Participants will complete approximately 80 trials. Participants are told that two of their choices will be randomly selected for payout at the appropriate time. Outcome variables include the proportion of choices for immediate/sooner rewards, as well as discounting parameter k, obtained by fitting choice data for each subject to a hyperbolic discount function. The task takes approximately 15 minutes to complete.
30 minutes after turning OFF DBS stimulation, participants will either remain in the OFF condition or will have the DBS turned ON, depending on their counter-balanced condition assignment. Subjects will complete the tasks above in the first condition. Following task completion, subjects will have DBS stimulation turned OFF or ON (again, depending on condition assignment). After 30 minutes, participants will complete the same tasks in the second condition. Following retesting, participants that were in the OFF condition will return to ON DBS stimulation.
The investigators will be using the implanted pulse generator to deliver a safe current. Because the investigators are not changing the therapeutic parameters of stimulation, subjects should not experience any changes during the ON condition. Should any discomfort arise in the OFF condition, the subject will be able to terminate the study and return to the ON condition immediately. The computer will register the subject's performance.
Electroencephalography recordings (EEG) will be acquired during performance of the aforementioned tasks. Continuous EEG data will be sampled at a maximum of 1024Hz using a 64-electrode cap. Eye movement artifacts will be assessed using bipolar electrodes.
Patients with just major depressive disorder or obsessive compulsive disorder will also be recruited as a control group for the patients with deep brain stimulation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Deep Brain Stimulators
Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
No interventions assigned to this group
Patients with MDD or OCD
Patients with MDD or OCD who do not have a deep brain stimulator.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed (as determined by the Handedness Inventory; Oldfield, 1971)
* Normal or corrected-to normal vision and hearing
* Current diagnosis of MDD or OCD
Exclusion Criteria
* Dementia or other known cognitive deficit
Psychiatric Patients:
* Clinical history of bipolar disorder
* Current or past psychotic disorder
* Gross structural brain damage
* Cognitive impairment that would affect a participant's ability to give informed consent
* Current substance abuse, or abuse within the past 3 months
* Clinical history of severe personality disorder
* Imminent risk of suicide or an inability to control suicide attempts
* Evidence of dementia or other significant cognitive impairment on neuropsychological evaluation
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Darin Dougherty, MD
Associate Professor of Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darin D Dougherty, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Massachusetts General Hospital
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011P002546
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.